Not provided
Not provided
Not provided
Not provided
Not provided
Unsatisfactory filter deployment in several cases
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the safety and effectiveness of the LUMIFI with Crux VCF System for deployment of the Crux VCF. The study will compare the method of Crux VCF deployment using the LUMIFI with Crux VCF System (IVUS guidance) with the historical results of the Crux VCF System (fluoroscopic guidance). The study will include enrollment into a roll in phase consisting of 2 study subjects per site prior to enrollment into the primary treatment phase for primary analyses. The purpose of the roll in phase is to assure compliance with site training on the use of the investigational device and protocol workflow.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Single-arm | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| vena cava filter implantation (LUMIFI with Crux VCF System) | Device |
|
| Measure | Description | Time Frame |
|---|---|---|
| Technical Success Rate | All Subjects, Cohort A and Cohort B were included in the safety analysis. The primary endpoint of effectiveness, defined as technical success included only subjects within Cohort B. Technical success of filter placement is defined as the primary deployment of the filter such that the investigator judges the location to be suitable to provide sufficient mechanical protection against pulmonary embolism. Due to early stoppage of the study, enrollment of 100 subjects required to test the null hypothesis and evaluate the Primary Endpoint of Technical Success was not achieved. Therefore, a formal analysis of Technical Success was not performed. | Day 1 |
Not provided
Not provided
Inclusion Criteria:
Patient is >18 years of age.
Patient or their legally authorized representative understands the research nature of the study and is willing and capable of providing informed consent
Patient has appropriate femoral vein access
Patient at risk for PE and meets at least one of the following sets of conditions:
a. Documented DVT or PE and: i. Inability to anticoagulate the patient due to risk of bleeding such as recent surgery, trauma, intracranial bleed, GI bleed, OR ii. Progression/recurrence of DVT or PE on therapeutic anticoagulation, OR iii. Inability to anticoagulate due to high risk of tumor bleeding, OR iv. Patient unable to safely comply with anticoagulation, OR v. Patient that needs interruption of therapeutic anticoagulation such as at the time of an operation or other procedure.
b. Patient that is high risk for DVT or PE and cannot be safely anticoagulated such as severe multi-trauma patient or patient having procedure with high risk for thromboembolism such as bariatric surgery.
c. Patients with DVT at high risk for PE and free floating iliac or caval thrombosis d. Patients with compromised cardiopulmonary reserve from existing PE with right heart failure/strain who could not tolerate any further insult from new PE
Exclusion Criteria:
Patient has any one of the following conditions:
Patient has a known allergy or intolerance to polytetrafluoroethylene (PTFE) or Nitinol (nickel-titanium)
Patients unwilling or unable to comply with the protocol
Patients with history of or known reaction or sensitivity to contrast agent that cannot be pre-medicated
Female patient of childbearing potential who is pregnant (she must have negative pregnancy test within the 48 hours prior to implantation and any retrieval procedure)
Patient is participating in another device or drug clinical trial or has participated in such trial in the 30 days prior to enrollment
Investigator considers patient to be a poor candidate for the study or believes that the patient may compromise the study, e.g., concomitant conditions (reasons will be documented)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Donald Jacobs, MD | St. Louis University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Surgical Care Associates | Louisville | Kentucky | 40207 | United States | ||
| Vascular Access Solutions |
This was a prospective, single-arm, multicenter clinical study to evaluate the safety & effectiveness of the LUMIFI with Crux VCF system. The study included enrollment into a roll-in phase Cohort A consisting of 2 subjects/ site to assure compliance with the Investigational Device prior to enrolling into Cohort B, the treatment phase.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | LUMIFI With Crux VCF System | vena cava filter implantation (LUMIFI with Crux VCF System). Includes both Cohort A and Cohort B subjects. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | LUMIFI With Crux VCF System | vena cava filter implantation (LUMIFI with Crux VCF System) |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Technical Success Rate | All Subjects, Cohort A and Cohort B were included in the safety analysis. The primary endpoint of effectiveness, defined as technical success included only subjects within Cohort B. Technical success of filter placement is defined as the primary deployment of the filter such that the investigator judges the location to be suitable to provide sufficient mechanical protection against pulmonary embolism. Due to early stoppage of the study, enrollment of 100 subjects required to test the null hypothesis and evaluate the Primary Endpoint of Technical Success was not achieved. Therefore, a formal analysis of Technical Success was not performed. | Posted | Count of Participants | Participants | Day 1 |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | LUMIFI With Crux VCF System | vena cava filter implantation (LUMIFI with Crux VCF System) |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Pulmonary Emboli Bilaterial | Vascular disorders | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| VP Clinical Trials | Volcano | 858-720-8731 | jonathan.batiller@philips.com |
Not provided
| ID | Term |
|---|---|
| D011655 | Pulmonary Embolism |
| D020246 | Venous Thrombosis |
| ID | Term |
|---|---|
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D004617 | Embolism |
| D016769 | Embolism and Thrombosis |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Orangeburg |
| South Carolina |
| 29118 |
| United States |
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Cohort A |
Roll-in phase consisting of 2 subjects per site to assure compliance with use of the Investigational Device |
| OG002 | Cohort B | Subjects are enrolled into Cohort B after each site has enrolled 2 subjects in Cohort A to assure compliance with use of the Investigational Device |
|
|
| 0 |
| 21 |
| 2 |
| 21 |
| Filter deployed too low | Vascular disorders | Systematic Assessment |
|
Principal Investigator shall have the right to publish or otherwise make public any data resulting from the study upon the earlier of (a) publication of a multi-center publication (or any publication, if the Study is not a multi-center study) coordinated by Sponsor with respect to the data resulting from the study, and (b) eighteen (18) months after the Study is completed at all participating sites if a multi-center publication.
| D014652 |
| Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D013927 | Thrombosis |